Keywords: new, data, confirms, gsk, requip, potential, therapy
New data confirms GSK's Requip as a potential therapy for restless legs syndrome
Article | 03 May 2004
GlaxoSmithKline's Requip (ropinirole) produces long-term improvements in symptoms of restless legs syndrome, as well as health-related quality of life (HRQoL) ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- US Supreme Court says patent settlement can "sometimes" be illegal
